Are biopsy specimens predictive of HER2 status in gastric cancer patients?

Pirrelli, M; Caruso, M L; Di Maggio, M; Armentano, R; Valentini, A M

Pirrelli, M; Caruso, M L; Di Maggio, M; Armentano, R; Valentini, A M.

Affiliation

Pirrelli M; Department of Pathology, Scientific Institute for Digestive Diseases S de Bellis, via Turi 27, Castellana Grotte, BA, Italy. michelepirrelli@libero.it

Dig Dis Sci ; 58(2): 397-404, 2013 Feb.

Article in En | MEDLINE | ID: mdl-22918687

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Biopsy/methods; Receptor, ErbB-2/metabolism; Stomach Neoplasms/drug therapy; Stomach Neoplasms/secondary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/therapeutic use; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Biopsy/standards; False Negative Reactions; False Positive Reactions; Female; Gene Amplification; Humans; Immunohistochemistry/methods; Immunohistochemistry/standards; In Situ Hybridization/methods; In Situ Hybridization/standards; Male; Middle Aged; Predictive Value of Tests; Receptor, ErbB-2/genetics; Reproducibility of Results; Stomach Neoplasms/surgery; Trastuzumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Biopsy / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Dig Dis Sci Year: 2013 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google